ArticleAddictive behaviors2025
The Cannabis Use Disorder Identification Test - Consumption (CUDIT-C) as a targeted tool for cannabis use screening.
Article in Addictive behaviors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond cannabis use severity: associations of cannabis product type with sleep quality and mental health.Psychopharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aimed to evaluate the psychometric properties and predictive utility of the Cannabis Use Disorders Identification Test - Consumption (CUDIT-C), a concise alternative to the Cannabis Use Disorders Identification Test - Revised (CUDIT-R), across individuals with differing levels of cannabis use.
methodParticipants included infrequent (N = 108) and frequent cannabis users (N = 138) from two studies. A confirmatory factor analysis (CFA) was first conducted to test a two-factor model of the CUDIT-R, hypothesizing that the first two items (CUDIT-C) load onto one factor, while the remaining items load onto a second factor related to cannabis dependence and problems. The CUDIT-C and CUDIT-R were then assessed for their ability to predict cannabis-related outcomes, including self-reported use days over the past 30 days and peak plasma delta-9-tetrahydrocannabinol (THC) levels following acute use.
resultsThe two-factor model was a stronger fit to the data than the one-factor model. Among infrequent users, the CUDIT-C performed equivalently to the CUDIT-R. In frequent users, the CUDIT-C either matched or outperformed the CUDIT-R, including being a stronger predictor of peak THC levels, an established marker of hazardous cannabis exposure. Conclusion The CUDIT-C is a practical and effective tool for assessing cannabis use, particularly among frequent users. However, its utility may be limited for infrequent users due to restricted variability of use in this group. Future research should explore its application in clinical settings and diverse populations, as well as its potential for diagnosing cannabis use disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.